Laboratory measurement of the anticoagulant activity of edoxaban: a systematic review
- 11 February 2015
- journal article
- review article
- Published by Springer Nature in Journal of Thrombosis and Thrombolysis
- Vol. 39 (3), 288-294
- https://doi.org/10.1007/s11239-015-1185-7
Abstract
Edoxaban, an oral direct inhibitor of factor Xa, was recently approved in the United States and Japan for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation and for treatment of venous thromboembolism (VTE). It is also licensed in Japan for prevention of VTE after major orthopedic surgery. Although routine laboratory monitoring of edoxaban is not required, laboratory measurement may be desirable in special circumstances. Our objective was to provide a systematic review of current evidence on laboratory measurement of the anticoagulant activity of edoxaban. PubMed and the Cochrane Library were searched for studies that reported a relationship between coagulation tests and plasma edoxaban levels. Study quality was assessed using Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2). We identified 9 eligible studies. Anti-Xa activity is linear across a broad range of drug levels (R 2 > 0.95) and may be used for edoxaban quantification. The assay shows greater variability at above on-therapy drug concentrations. The PT is less sensitive to edoxaban. A normal prothrombin time may not exclude clinically relevant on-therapy drug levels. The activated partial thromboplastin time has insufficient sensitivity to edoxaban for measurement of its anticoagulant activity. Edoxaban exhibits variable effects on coagulation assays. Understanding these effects facilitates interpretation of test results in edoxaban-treated patients. More data on the relationship between drug levels, coagulation test results, and clinical outcomes in patients are needed.Keywords
This publication has 18 references indexed in Scilit:
- Bioavailability and Safety of the Factor Xa Inhibitor Edoxaban and the Effects of Quinidine in Healthy SubjectsClinical Pharmacology in Drug Development, 2013
- Reversal of anticoagulant effects of edoxaban, an oral, direct factor Xa inhibitor, with haemostatic agentsThrombosis and Haemostasis, 2012
- QUADAS-2: A Revised Tool for the Quality Assessment of Diagnostic Accuracy StudiesAnnals of Internal Medicine, 2011
- In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinuxThrombosis Research, 2011
- Effects of Food on the Pharmacokinetics of Edoxaban, an Oral Direct Factor Xa Inhibitor, in Healthy VolunteersThe Journal of Clinical Pharmacology, 2011
- Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinuxThrombosis and Haemostasis, 2011
- Safety of edoxaban, an oral factor Xa inhibitor, in Asian patients with non-valvular atrial fibrillationThrombosis and Haemostasis, 2011
- Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillationThrombosis and Haemostasis, 2010
- DU‐176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profilesJournal of Thrombosis and Haemostasis, 2008
- Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamberThrombosis and Haemostasis, 2007